section name header

Pronunciation

be-TAX-oh-lol

Classifications

Therapeutic Classification: antihypertensives

Pharmacologic Classification: beta blockers

Indications

REMS


Action

  • Blocks stimulation of beta1 (myocardial) adrenergic receptors. Does not usually affect beta2 (pulmonary, vascular, uterine) receptor sites.
Therapeutic effects:
  • Decreased BP and heart rate.

Pharmacokinetics

Absorption: Well absorbed after oral administration.

Distribution: Widely distributed.

Metabolism/Excretion: Mostly metabolized by the liver, 20% excreted unchanged by the kidneys.

Half-Life: 15–20 hr.

Time/Action Profile

(antihypertensive effect)

ROUTEONSETPEAKDURATION
PO3–4 hr3–4 hr24 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: HF, BRADYCARDIA, hypotension, peripheral vasoconstriction, PULMONARY EDEMA

Derm: rashes

EENT: blurred vision, stuffy nose

Endo: hyperglycemia, hypoglycemia

GI: liver enzymes, constipation, diarrhea, nausea, vomiting

GU: erectile dysfunction, libido, urinary frequency

MS: arthralgia, back pain, joint pain

Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nightmares

Resp: bronchospasm, wheezing

Misc: drug-induced lupus syndrome

Interactions

Drug-drug:

Route/Dosage

Renal Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Kerlone